Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DDI Study of TAK-272 with Itraconazole, Digoxin, or Midazolam
NCT02370615Phase 1Completed
- Sponsor
- Takeda
- Start
- Feb 2015
- Primary completion
- Apr 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of imarikiren in hypertension (HTN) (2 cohorts), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration at Day 10, Area Under the Plasma Concentration-time Curve From Time 0 to Infinity at Day 10 and 8 more. Started Feb 2015; status: completed.
02
Drugs
imarikiren
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT02370615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02370615.